Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752447 | 0.94 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3978059 | 0.87 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3973843 | 0.85 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL4082265 | 0.80 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3978687 | 0.78 | MAPK14 (1.00) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL13548217 | 0.77 | MAPK14 (0.62) | MAPK14MAPK13 | |
| SCHEMBL3632376 | 0.77 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL4131360 | 0.74 | MAPK14 (0.72) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3636242 | 0.72 | MAPK14 (0.85) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL4090471 | 0.72 | MAPK14 (1.00) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2009055033-A1 | PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-04-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | MAPK14 52/4885CYP2D6 422/4885CYP2C9 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.